Posts by Selector

Jahresergebnis 2018

Das war doch sehr gut:

Partners Group steigert 2018 Umsatz und Gewinn - Dividendenerhöhung

• [Blocked Image: https://premium.swissquote.ch/sqi_premium/FileServlet?file=news_images/m_87854372.jpg]
• [Blocked Image: https://premium.swissquote.ch/sqi_premium/FileServlet?file=news_images/m_87854382.jpg]
• [Blocked Image: https://premium.swissquote.ch/sqi_premium/FileServlet?file=news_images/m_87854344.jpg]

< >

Zürich (awp) - Der Vermögensverwalter Partners Group hat im vergangenen Jahr erneut Umsatz und Gewinn gesteigert. Mit der angekündigten Ausschüttung einer deutlich höheren Dividende wurden die Markterwartungen übertroffen.

Ein solides Finanzergebnis über alle Bereiche hinweg habe zum Vorschlag geführt, die Dividende zu erhöhen, teilte der auf Privatmarktanlagen spezialisierte Asset Manager am Montag mit.

Die Erträge erhöhten sich im Geschäftsjahr 2018 um 7 Prozent auf 1,33 Milliarden Franken. Insbesondere die Management-Gebühren, die üblicherweise den Grossteil der Einnahmen ausmachen, stiegen stark an.

Der Betriebsgewinn (EBITDA) stieg um 7 Prozent auf 882 Millionen Franken an. Die entsprechende Marge hielt sich bei 66 Prozent. Unter dem Strich legte der Reingewinn um 2 Prozent auf 769 Millionen Franken zu. Die Aktionäre sollen in den Genuss einer Dividende in der Höhe von 22 Franken je Aktie kommen nach 19 Franken im Vorjahr.

Mit den Resultaten hat der Vermögensverwalter die Erwartungen am Markt genau erreicht beziehungsweise übertroffen. Von AWP befragte Analysten hatten im Durchschnitt Erträge in Höhe von 1,32 Milliarden Franken erwartet. Der EBITDA wurde auf 857 Millionen und der Reingewinn auf 768 Millionen geschätzt. Die Prognose für die Dividende hatte auf 20,90 Franken gelautet.

Wie bereits seit Mitte Januar bekannt, sind die verwalteten Vermögen per Ende 2018 um 18 Prozent auf 72,8 Milliarden gestiegen. Zu dem Wachstum beigetragen hatten neue Kapitalzusagen in Höhe von 13,3 Milliarden Euro und damit gleich viel wie im Vorjahr.

Für das laufende Geschäftsjahr rechnet Partners Group mit Kapitalzusagen von brutto 13 Milliarden bis 16 Milliarden Euro, wie frühere Aussagen bestätigt wurden. Zudem kalkuliert das Unternehmen mit Tail-Down-Effekten in Höhe von 6,5 Milliarden bis 7,5 Milliarden. Die höheren erwarteten Tail-Down-Effekte im Jahr 2019 führt das Management darauf zurück, dass grössere Investitionsprogramme auslaufen werden.

Bei Partners Group ist der Grossteil der Produkte darauf ausgelegt, dass Investoren zehn bis zwölf Jahre fest investiert bleiben. Wenn ein Privatmarktprogramm ausläuft, reduzieren sich die verwalteten Vermögen schrittweise, was als Tail-Down-Effekt bezeichnet wird.

ys/rw

Quelle Swissquote

[Blocked Image: https://premium.swissquote.ch/gifs/new_logo_awp.gif]

FSLR Zahlen / Q4 & Full Year 2018

https://investor.firstsolar.co…cial-Results/default.aspx

und sie kommen hoch...

ACB

Danke @ Ben für die Zahlen (Q2) von Aurora.

Die guten Prognosen sollten eigentlich motivieren. Zurzeit dürften die Aurora noch käufig sein. Wer auf das Ganzjahresergebnis (Q4) in der Jahresmitte 2019, warten will...na ja...

Übrigens sehen wir am 14. Februar, afte market, noch das Q3 von Canopy Growth (CGC/WEED). Bin mal gespant.

Infos

*smile* *dirol* Da sollte man wohl in der Branche mindestens mit einem Bein drin sein / bleiben:

HINTERGRUND-Nach der Potcom-Blase - Cannabis-Branche wird erwachsen 19-12-2018 15:29

* Cannabis-Branche wächst dank zunehmender Legalisierung

* Getränke- und Tabakindustrie investiert Milliarden

* Aktien sind nach Rekordwerten im Herbst aber auf Talfahrt

- von Patricia Weiss

Frankfurt, 19. Dez (Reuters) - In der Cannabis-Branche herrscht Goldgräberstimmung. Anleger, die ihr Geld in börsennotierte Produzenten wie Canopy Growth und Aurora Cannabis steckten, konnten sich in den vergangenen zwei Jahren eine goldene Nase verdienen. Inzwischen ist etwas Ernüchterung eingekehrt: Seit Kanada im Oktober als weltweit erste große Industrienation den Cannabis-Konsum vollständig freigab, gingen die Kurse nach unten, auch wegen schwächer als erwarteter Geschäftszahlen. "Die Aktien waren ein absoluter Spielball von Zockern", sagt Analyst Jochen Stanzl vom Broker CMC Markets. Dieser Hype sei vorbei. "Die Frage ist nun, wie sich die Unternehmen dieser Branche etablieren." Denn auch wenn sich Anleger 2019 dem nächsten Trendthema zuwenden dürften, sind sich Experten einig: Die Cannabis-Industrie ist auf Wachstumskurs, die Nachfrage ist riesig - als Genussmittel sowieso, aber immer mehr auch zu medizinischen Zwecken.

Seit Anfang 2017 bis zu den Höchstständen im Oktober dieses Jahres legten die Aktien von Branchengrößen wie Canopy Growth und Aurora Cannabis um 670 Prozent beziehungsweise 650 Prozent zu. Seitdem haben die Aktien der Cannabis-Firmen an der Börse aber teilweise mehr als die Hälfte an Wert eingebüßt. Der nordamerikanische "Marijuana Index", in dem die führenden Unternehmen der Branche aus den USA und Kanada gelistet sind, hat seit seinem Rekordhoch im Herbst rund die Hälfte verloren. CMC-Analyst Stanzl spricht von einer Blase, die geplatzt ist. "Von der Psychologie war das vergleichbar mit Bitcoin." Für einen digitalen Taler mussten Anleger vor einem Jahr knapp 20.000 Dollar auf den Tisch legen, inzwischen kostet Bitcoin gerade noch 3200 Dollar.

Einig sind sich Experten aber, dass es sich bei Cannabis im Gegensatz zum Bitcoin um ein echtes Produkt mit großem Marktpotenzial handelt. "Bei den großen kanadischen Herstellern haben wir erstaunliche Wachstumsraten gesehen. Das wird in der Geschwindigkeit möglicherweise nicht so weitergehen, aber es wird aus meiner Sicht zu weiterem signifikantem Wachstum kommen", sagt Peter Homberg, Partner und Leiter der Life-Science-Praxis bei der Wirtschaftskanzlei Dentons.

Auch Marktforscher zeichnen ein positives Bild und überbieten sich in ihren euphorischen Prognosen: Bis 2022 dürften die weltweiten Ausgaben für legales Marihuana nach Einschätzung von BDS Analytics und Arcview auf 32 Milliarden Dollar steigen, 2017 waren es noch 9,5 Milliarden. 41 Prozent dürften bis dahin alleine auf Kanada und Kalifornien entfallen. Kalifornien zählt zu einer Reihe von US-Bundesstaaten von Colorado bis Washington, in dem der Cannabis-Konsum bereits vollständig legal ist. Aber auch Europa spielt eine immer wichtigere Rolle. Dort erlauben mehr als 20 Länder medizinisches Cannabis, darunter Deutschland seit März 2017. Die Marktforscher von Prohibition Partners trauen alleine Europa bis 2028 ein Marktpotenzial von knapp 116 Milliarden Euro (knapp 132 Milliarden Dollar) zu. Das setzt allerdings eine vollständige und eher unwahrscheinliche Legalisierung auf dem gesamten Kontinent voraus.

GENUSSMITTEL ODER SCHMERZKILLER

Welche Unternehmen können am meisten Geschäft abschöpfen? Zu den Erfolgsfaktoren zählen nach Einschätzung der Analysten der Berenberg Bank Größe, Produktvielfalt, Marken sowie der Marktzugang. Dabei sehen sie Canopy Growth am besten positioniert, sowohl auf dem Heimatmarkt Kanada als auch international. Das Unternehmen hat zudem einen starken Partner im Rücken: Der Corona-Bier-Hersteller Constellation Brands pumpte im August vier Milliarden Dollar in Conopy und baute seinen Anteil auf 38 Prozent aus. Zusammen wollen die beiden Firmen cannabishaltige Getränke entwickeln - ein Trend, den auch Coca Cola nach eigenen Angaben genau beobachtet. Dem weltgrößten Getränkekonzern wurde Interesse am Canopy-Rivalen Aurora nachgesagt. Einen Schritt weiter ist bereits der Tabakkonzern Altria. Der Marlboro-Hersteller stieg kürzlich bei dem kanadischen Produzenten Cronos für 1,8 Milliarden Dollar ein.

Während Nordamerika bei der Legalisierung von Cannabis als Genussmittel eine Vorreiterrolle einnimmt, steht in Europa die Freigabe zu medizinischen Zwecken im Fokus. Erst im November legalisierte Großbritannien medizinisches Cannabis. Die Wirkstoffe können unter anderem Schmerzen bei Krebserkrankungen, Übelkeit nach Chemotherapien oder Spastiken bei Multipler Sklerose lindern. "Wir sehen eine starke Entwicklung hin zur medizinischen Verwendung in allen möglichen Ländern, das ist ein riesiges Potenzial", ist sich Georg Wurth, Geschäftsführer beim Deutschen Hanfverband, sicher. Nach seinen Schätzungen gibt es in Deutschland rund 30.000 Patienten, die Cannabis von der gesetzlichen Krankenkasse erstattet bekommen, Tendenz steigend. Bislang wird der hiesige Bedarf noch über Importe gedeckt. Erst ab 2020 dürfte nach Einschätzung des Bundesinstitut für Arzneimittel und Medizinprodukte Cannabis auch aus Anbau in Deutschland zur Verfügung stehen. Das Institut hat Aufträge zur Produktion von medizinischem Cannabis in Deutschland ausgeschrieben, die Bewerbungsfrist dafür endete erst vor wenigen Tagen.

(Mitarbeit von Patricia Uhlig, redigiert von Kathrin Jones. Bei Rückfragen wenden Sie sich bitte an die Redaktionsleitung unter den Telefonnummern 069-7565 1232 oder 030-2888 5168.) ((patricia.weiss@thomsonreuters.com; +49 69 7565 1337; Reuters Messaging: patricia.weiss.reuters.com@reuters.net, http://www.twitter.com/REUTERS_DE, http://www.reuters.de))

[Blocked Image: https://premium.swissquote.ch/gifs/logo_thomson_reuters.gif]

Quelle Swissquote

First Solar Pronosen 2019

Info

First Solar macht gute Prognosen für 2019. Trader sollten wohl mal wieder hinschauen.-

https://www.pv-magazine.com/20…-doubling-coming-in-2019/

Aurora-News

Anbei mal wieder etwas Neues von ACB:

https://www.stockwatch.com/New…spx?bid=Z-C%3aACB-2695149

ACB-News (inkl. Q1-Bericht)

Hier mal wieder was von ACB:

Das fehlt hier wie ich sehe

BRIEF-Aurora Cannabis Reports Q1 Revenue Of $29.7 MLN VS $8.3 MLN

Nov 12 (Reuters) - Aurora Cannabis Inc :

* AURORA CANNABIS ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2019

* AURORA CANNABIS INC QTRLY REVENUE$29.7 MILLION VERSUS $8.3 MILLION

* AURORA CANNABIS INC QTRLY CASH COST OF SALES PER GRAM OF DRIED CANNABIS SOLD OF $1.90

* AURORA CANNABIS INC QTRLY GROSS MARGIN ON CANNABIS OF 70%, UP 12%

* AURORA CANNABIS - SEES AROUND YEAR END 2018 INTO BEGINNING OF CALENDAR 2019, CO WILL HAVE PRODUCTION RUN RATE IN EXCESS OF 150,000 KG PER ANNUM

* AURORA CANNABIS INC - EXPECTS TO SUBSEQUENTLY SCALE UP PRODUCTION RUN RATE TO OVER 500,000 KG PER ANNUM INTO CALENDAR 2019

* AURORA CANNABIS INC QTRLY NET INCOME $104.2 MILLION VERSUS $3.6 MILLION

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

EDMONTON, Nov. 12, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX | NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM), announced today its financial and operational results for the first quarter ended September 30, 2018.

Q1 2019 Financial and Operational Highlights

Commencement of Sales to Canadian Adult Consumer Use Market

On October 17, 2018, sales of cannabis for adult consumer use in Canada, legalized through Bill C45, commenced. Aurora recorded a strong performance, ranking top or among the top selling products and brands in many of the provinces the Company committed to supplying, for the first two weeks to October 31, 2018.

Provincial Highlights (for the period up to October 31, 2018):

• ON (Source: Ontario Cannabis Store (OCS) website)
  • Aurora brands accounted approximately 30% of the total market supplied through the OCS
  • San Rafael was the top selling brand in ON with Aurora supplying two of the three top selling products
• BC (Source BC government website – data current as of Nov 2nd)
  • Top 4 best-selling dried flower products in BC
  • 2 of top 5 and 3 of top 8 best-selling oil and capsule products in BC
• PEI (Source: PEI government sales report – data current as of Nov 2)
  • Aurora and MedReleaf are 2 of the 6 top best-selling LPs in the province
  • 2nd largest for overall revenue
• More than 450 unique SKUs launched across Canada

Q1 2019 Highlights:

• Revenue of $29,674, up 260% compared to the same period in 2018.
  • Pro-forma Q1 2019 revenue of $35,752, including MedReleaf (consolidated as of July 25, 2018), Anandia (consolidated as of August 8, 2018) and Agropro (consolidated as of September 10, 2018)
• Gross margin on cannabis of 70%, up 12% points compared to the first quarter of 2018, and down slightly by 4% points compared to Q4 2018. The increase versus Q1 2018 was primarily due to a higher average selling price per gram of dried cannabis, coupled with a higher proportion of cannabis oil sales in the Company's sales mix ratio. The slight decrease from Q4 2018 was due to higher average packaging costs related to the inclusion of MedReleaf's relatively higher packaging costs and an overall increase in packaging costs due to the stringent regulatory requirements of the Cannabis Act.
• Cash cost of sales decreased by 12.0% compared to Q1 2018 and increased slightly by 1.6% compared to Q4 2018. Cash cost to produce per gram of dried cannabis sold decreased 22.5% compared to Q1 2018 and fell by 14.7% compared to Q4 2018. This decrease was primarily due to more efficient production processes rapidly implemented post-acquisition at the Company's subsidiary CanniMed.
• Active registered medical patients of 67,484, up 250% compared to the first quarter of 2018.
• Kilograms produced and kilograms sold of 4,996 and 2,676, up 395% and 201%, respectively, as compared to the same period in 2018.
• 8 facilities with production licenses, 6 facilities with sales licenses, including Aurora Sky.
• Introduced Aurora Cloud, making Aurora the first and, to the company's knowledge, only LP supplying a vape-ready CBD oil cartridge to the market.

Management Commentary

"We continue to successfully execute our differentiated and diversified strategy committed towards domestic and international expansion in the medical cannabis market, adult consumer use sales, production scale-up, innovation, plant and medical research, and product development," said Terry Booth, CEO of Aurora. "The commencement of adult consumer use sales in Canada has been very successful for Aurora, with strong performance across all product categories and brands. Our initial roll-out success demonstrates how our high-quality Aurora Standard products and well-positioned brands have resonated strongly with the consumer market and our preparedness for the logistical challenges in effectively bringing our products to market. Given the strong unmet consumer demand evident across Canada, we are confident that our rapidly increasing production capacity will result in continued acceleration of revenue growth."

Mr. Booth added, "We also continue to perform well in our international medical business. With the acquisition of ICC Labs, which we expect to close in the coming weeks, we are establishing leadership in Latin America. In addition to ongoing international growth and expansion led by our team at Aurora Europe, we were also the first non-government organization to export medical cannabis to Poland, a medical market with a population roughly equal to Canada. Across our international activities, we have established significant early mover advantage and market leadership. With the scale-up of our domestic and international production facilities, we anticipate increased availability of product to service these developing markets which will drive further global growth for the Company."

Glen Ibbott, CFO, added, "In Q1 2019, we continued to propel Aurora's growth making critical investments in our corporate, sales, and marketing talent and capabilities. A significant portion of our Q1 2019 marketing spend was in preparation for the adult consumer use market with numerous branding and market awareness initiatives. With more restrictive marketing regulations in effect as of October 17th, we will see a significant reduction in average marketing spend over the remainder of the fiscal year. We also anticipate a reduction in other one-off expenditures, such as the integration costs related to the MedReleaf, CanniMed, and Anandia acquisitions."

Mr. Booth concluded, "As a science, medical and patient focused organization, we are committed to continue serving our patients with the products they require. As we built up inventory levels in anticipation of the adult consumer use market, we prioritized product availability for our over 67,000 existing patients. With production ramping up, we anticipate once again pro-actively driving additional growth in this core medical segment, both domestically and internationally."

Q1 2019 and Subsequent Operational Highlights

Facilities and Production update

During and subsequent to the quarter, the Company made significant progress towards increasing its production capacity, including receipt of various sales and production licenses. Based on grow rooms in production, the Company currently is running at an annualized run rate of 70,000 kg. Management anticipates that around calendar year end 2018 into the beginning of calendar 2019, Aurora will have a production run rate in excess of 150,000 kg per annum based on grow rooms in production, with subsequent scale up to over 500,000 kg per annum (excluding additional capacity through the acquisition of ICC Labs).

Aurora Sky

On October 17, 2018, the Company received its Health Canada sales license for Aurora Sky, allowing Aurora to increase product availability across Canada. Facility construction is now materially complete, including exterior structure, landscaping, commissioning, and harvest and waste rooms.

Aurora continues to populate additional bays at the facility, with all 17 rooms anticipated to be ready to receive plants within the coming month, and the facility fully planted around calendar year end, ramping up to full capacity. The recently planted rooms were populated using the successfully commissioned automation systems, which function as anticipated, resulting in substantially increased facility efficiencies as compared to traditional greenhouses or indoor grow facilities.

Aurora Sky is a technologically highly sophisticated facility, built to deliver exceptional operational efficiencies, including energy, water and nutrient use. In addition to harnessing the power of the sun through the use of highly specialized glass with strong light diffusing characteristics, the Company captures the excess heat generated in the facility during the day, storing it in the successfully commissioned heat sink to be reused when additional heat energy is required, usually during night time hours. The facility is also set up to harness the higher ambient temperatures during the warmer months to supply additional free heat, while the colder months provide free additional cooling capacity.

The electricity consumed by the facility is supplied through two independent sub-stations, which feed two independent electrical rings. The rings have interconnects, as well as a back-up independent power generator, to ensure full redundancy. Furthermore, the electrical rings are monitored and controlled by a digitalized management system with switch gear to move power through the facility quickly and efficiently.

The measures described above ensure a very significant reduction in energy use compared to more traditional facilities that yield a similar production output on an annual basis.

Aurora Mountain

On July 30, 2018, the Company received a Health Canada dealer's license for its Mountain Facility in Cremona, Alberta. This license allows Aurora to expand research and product development activities with cannabinoids and their derivatives not covered under the Cannabis Act, as well as import and export cannabis products to and from international markets, subject to applicable regulations.

On September 28, 2018, Aurora Mountain also received its Health Canada production license to produce encapsulated oils. Aurora is producing unique, integral hard-shell capsules for the medical and adult consumer use markets.

Aurora Vie

The Company received its sales license for Aurora Vie in July 2018. The facility is now operating at full capacity, producing at a run rate of 4,000 kg per annum.

On August 22, 2018, the Company received Health Canada authorization to begin production of cannabis softgel capsules at its Aurora Vie facility in Pointe-Claire, Quebec. On October 17, 2018, the Company received its Health Canada softgel sales license. The Company utilizes technology it has exclusively licensed from strategic partner Capcium, in which Aurora has a strategic investment. High volume production of softgels at Vie has started, resulting in greater availability of this higher margin product.

Aurora Eau

On September 7, 2018, Aurora received a Health Canada production license for its Eau facility in Lachute, Quebec. Aurora Eau was purpose-built to EU GMP standards and represents the next evolution of Aurora's indoor-grow facilities, where novel and exotic strains will be grown for both the medical and adult consumer-use markets. Aurora Eau, which is fully planted with first harvest anticipated shortly, was officially opened on November 5, 2018.

Aurora Nordic, Phase I and II

On August 13, 2018, the Company successfully shipped cultivars from Aurora Mountain to Odense, Denmark to commence populating the Aurora Nordic Phase I facility, named "Base One". The facility is ramping up to its full 8,000 kg per annum capacity, increasing product availability for the EU markets. The Company has commenced with a 54,000 square feet expansion of Base One, anticipated to be fully completed towards the end of the first calendar quarter of 2019. Pharma-grade processing equipment will be moved into the facility, with completion and full commission anticipated for early 2019.

Construction of Aurora Nordic Phase II, named "Nordic Sky", has commenced with site preparation, ground and drainage work.

MedReleaf Markham

On August 13, 2018, Aurora, through its wholly-owned subsidiary MedReleaf, received EU GMP certification on its facility in Markham, Ontario. This certification will allow MedReleaf Markham to access rapidly growing, higher margin, heavily regulated EU markets.

MedReleaf Bradford

On September 7, 2018, the Company, through its wholly-owned subsidiary MedReleaf, received its Health Canada oils production license for its facility located in Bradford, Ontario. This license allows MedReleaf Bradford, a 210,000 square foot facility which features a high-volume CO2 extraction facility, to significantly increase the production of oils in fiscal 2019. MedReleaf Bradford continues to produce oils, a higher-margin product, in anticipation of the receipt of its oils sales license.

To date, Bradford has completed 13 cultivation rooms, 5 drying rooms, 2 trim rooms, an extraction room, packaging area and the vault. Two additional grow rooms were recently commissioned with only two grow rooms remaining to be licensed.

Aurora Sun

On April 16, 2018, the Company acquired approximately 71 acres of land in Medicine Hat, Alberta, for the construction of "Aurora Sun", a 1.2 million square foot, highly automated cannabis production facility with ultra-low operating costs. Construction of Aurora Sun is on schedule with site preparation, backfilling, and 80% of pilings completed to date. Aurora expects to commence erecting the buildings metal frame in the beginning of calendar year 2019. Near completion of the piling work is a major milestone as it ensures greater efficiency of construction work during the winter months.

CanniMed

On July 3, 2018, the Company, through its wholly-owned subsidiary, CanniMed, received Health Canada authorization to commence sales of CanniMed capsules, a line of vegan capsules which became available to patients on August 22, 2018. Facility upgrades are continuing, and increased yields and efficiencies are already being realized.

Innovation

The Company is successfully executing on a comprehensive innovation strategy that covers the entire cannabis industry value chain from breeding and genetics, through facility development to medical research product development and post production analytics. Objective of the innovation strategy is to yield industry leading operational efficiencies, as well as the development of a broad portfolio of high-margin, targeted medical and consumer use products.

Medical Research

• Through the combination of the science teams at Aurora, CanniMed, MedReleaf and Anandia, the Company is engaged in industry leading medical research in multiple therapeutic areas, which management anticipates will yield marketable IP and fuel product development with targeted therapeutics. Therapeutic areas include pain, cancer, epilepsy, PTSD, anxiety, opioid sparing and neurodegeneration, as well as other areas. To date, Aurora and its subsidiaries have:
  • 40 clinical trials and case studies completed or in progress
  • 7 pre-clinical trials in progress
  • A multitude of studies under preparation

Product Development

• Launch of Vape-Ready, High-Potency CBD Oil Cartridges
  On October 16, 2018, the Company announced that it had received necessary compliance verification from Health Canada to sell its innovative, high-potency, vape-ready CBD oil product line under the brand Aurora Cloud. The first Aurora Cloud products released contain over 550mg of CBD and less than 30mg of THC, making them the only vape-ready CBD products legally available in Canada.
• The Company is developing a strong pipeline of new products under development, as well has entered into a number of strategic partnerships, with companies such as Capcium (production of softgels, underway at Aurora Vie), Wagner Dimas (pre-rolls, underway, SKUs being delivered to the adult usage market) and CTT Pharmaceuticals (sub-lingual wafers, working jointly towards obtaining approval for market introduction).

Acquisitions

Aurora has been executing successfully on developing a fully vertically integrated company. This strategy combines both organic initiatives and M&A. To date the Company has completed over 25 transactions (acquisitions and strategic investments), covering the entire spectrum of the cannabis industry value chain. Consequently, Aurora has been successful in establishing leadership across its activities and is exceptionally well positioned to capitalize on its early mover advantage globally, across its medical, wellness, and adult consumer use market segments.

• Acquisition of MedReleaf Corp. ("MedReleaf")
  On July 25, 2018, the Company completed the acquisition of MedReleaf, creating a vertically integrated cannabis industry leader, with a total funded capacity of more than 500,000 kg per year. Together with MedReleaf, Aurora now has two EU GMP certified production facilities, as well as an EU GMP certified distribution facility. Establishing an early mover advantage in the large European medical market.
• Acquisition of Anandia Laboratories Inc. ("Anandia")
  On August 8, 2018, the Company acquired all issued and outstanding shares of Anandia, a leading research and science focused company specializing in plant genetics and breeding, as well as providing analytical testing services to producers and patient-cultivators. This transaction enables the Company to develop new strains with specific terpene/cannabinoid profiles for targeted product applications, as well as strains with improved cultivation characteristics. Management believes these activities will lead to the development of new higher-margin products and a further increase in efficiency of the Company's cultivation process.
• Acquisition of ICC Labs Inc. ("ICC")
  On September 10, 2018, the Company entered into a definitive agreement to acquire all the issued and outstanding shares of ICC, whose shareholders voted in favour of the transaction at a special meeting of shareholders on November 6, 2018. ICC is a licensed producer, developer, and vendor of recreational and medical cannabis products and industrial hemp in Uruguay. Once completed, this acquisition will create a strong foundation for expansion and will leverage ICC's first mover advantage in South America, bringing significant low-cost production capacity of both THC and CBD based products in both Uruguay and Colombia. ICC has extensive distribution channels throughout South America and internationally, and will play an important role in the execution of the Company's strategy focused on the wellness market segment.
• Acquisition of UAB Agropro ("Agropro") and UAB Borela ("Borela")
  On September 10, 2018, the Company acquired all issued and outstanding shares of Agropro, Europe's largest producer, processor, and supplier of certified organic hemp and hemp products, as well as sister company Borela, a European hemp processor and distributor. This acquisition is anticipated to yield significant quantities of CBD for extraction and create further synergies through the Company's CBD and hemp product value chain, which includes Aurora's majority ownership of Hempco Food and Fiber.
• Acquisition of HotHouse Consulting Inc. ("HotHouse")
  On August 7, 2018, the Company entered into a Letter of Intent to acquire HotHouse, a provider of advanced greenhouse consulting services, specializing in hybrid greenhouse growing techniques. HotHouse founder and industry veteran, Laust Dam, has joined Aurora's wholly-owned subsidiary, Aurora Larssen Projects ("ALPS") as VP of Horticultural Development. This acquisition will allow Aurora to expand ALPS post-construction services offerings and provide customers with ongoing support and consulting by HotHouse crop specialists.

Strategic Investments

• Spin-out of Australis Capital Inc. ("ACI")
  On September 19, 2018, the Company successfully completed the spin-out of ACI, an investment company that intends to acquire ownership interest in a variety of opportunities and asset classes in the cannabis and real estate sectors in the United States. Shares and warrants of ACI trade on the Canadian Securities Exchange ("CSE") under the ticker symbol "AUSA". Eligible Aurora shareholders received one unit of ACI for every 34 Aurora shares outstanding as at August 24, 2018. Each unit consists of one common share and one warrant exercisable at $0.25 per warrant for a period of one-year. Following the distribution, Aurora has no direct ownership interest in ACI. Aurora, however, maintains strategic flexibility with share purchase warrants allowing the Company to acquire a significant ownership interest at such time in the future (within 10 years) when holding investments in U.S. cannabis assets will become legally permissible.

To date, ACI's management, board, and advisory teams have completed the following strategic investments and financing activities:

• October 3, 2018: Finalized a definitive agreement to purchase 2,200,000 shares of Wagner Dimas, a market leader in the development of unique, patented technology and proprietary processes that enable large-scale production for the higher-margin pre-rolled segment of the cannabis market.
• October 26, 2018: Completed a $30 million private placement
• November 5, 2018: Completed the acquisition of Rthm Technologies Inc., the number one health app in 26 countries, which holds several brand-associated trademarks and has developed the world's first mobile genetics and circadian rhythm mapping platform for both iOS and Android devices.
• November 5, 2018: Completed an investment agreement with Body and Mind Inc. ("BaM"), a publicly traded company that invests in high quality medical and recreational cannabis cultivation and production and retail. BaM products include dried flower, edibles, topicals, extracts as well as GPEN Gio cartridges.
  
• License for Pre-Roll Technology with CannaRoyalty Corp. ("CannaRoyalty")
  On August 1, 2018, the Company entered into an Assignment and Assumption Agreement with CannaRoyalty, whereby CannaRoyalty assigned to Aurora all its rights, title and interest in an exclusive license for pre-rolled cannabis technology developed by Wagner Dimas Inc ("Wagner Dimas"). This technology allows Aurora to target the high-volume, high-margin pre-rolled segment of the cannabis market.

The Wagner Dimas technology has now been installed at Aurora, and the large-scale production of pre-rolled product has commenced in order to fulfill orders received from provincial buyers who have begun supplying the Canadian adult-use market.

• Strategic Partnership with Evio Beauty Group Ltd. ("Evio")
  On July 10, 2018, the Company entered into a strategic partnership with Evio to collaborate on a line of co-branded hemp seed oil products ("non-infused products") and CBD-infused cosmetic products ("infused products"). Aurora anticipates that this partnership will result in greater brand recognition and cross-selling opportunities to customers of both companies.
• Strategic Investment in Choom Holdings Inc. ("Choom")
  On November 5, 2018, the Company announced it had completed an additional $20 million investment in Choom. Through this strategic investment, Aurora further diversifies its retail strategy, with additional retail opportunities across Western Canada, and future potential opportunities in the Ontario market.

International Expansion

• Aurora Europe
  On August 13, 2018, Aurora established a pan-European company, Aurora Europe GmbH ("Aurora Europe"), headquartered in Berlin, Germany. The Company has also incorporated and ramped up hiring at Aurora Deutschland GmbH (formerly Pedanios GmbH), Aurora Italia (Italy), Aurora Nordic (Denmark), and several other local companies under Aurora Europe.
• Letter of Intent for Production of Medical Cannabis in Malta
  On July 24, 2018, the Company announced that it received a Letter of Intent from Malta Enterprise, the Maltese government's economic development agency, to establish a facility focused on the production of high margin oils and cannabis derivative products in Malta. Aurora will be a majority shareholder in a newly established subsidiary, Aurora Malta, through a joint venture with a local Maltese partner, Cherubino Ltd.
• MedColombia SAS ("MedColombia")
  Through the acquisition of MedReleaf, Aurora acquired MedColombia, a licensed cannabis company based in Colombia with a strong portfolio of genetics. The Company's South American activities will be further integrated upon the completion of the ICC transaction.
• Exports to Australia
  During the first quarter of 2019, Aurora successfully completed its first export of cannabis oil products to Australia. The products were supplied to medical patients through its partner, Cann Group Ltd. ("Cann Group"), which Aurora maintains 22.9% ownership. Aurora and its wholly-owned subsidiary, Anandia, have also successfully exported plant tissue culture derived genetics which were used to enhance Cann Group's cultivation program. Cann Group is constructing an ALPS designed facility at the Melbourne International Airport.
• First Cannabis Import Permit from Polish Ministry of Health
  On October 25, 2018, the Company announced that it was granted approval from the Polish Ministry of Health to ship medical cannabis to a pain treatment center and a hospital in Warsaw, Poland. This is believed to be the first time a non-government run business has been granted approval to supply medical cannabis products in Poland, which have now been successfully shipped from Germany.

Financing and Capital Market Activities

• Bank of Montreal ("BMO") Debt Facility
  On August 29, 2018, the Company closed its previously announced debt facility with BMO, consisting of a $150 million term loan and $50 million revolving credit facility, both of which mature in 2021. The debt facility bears interest at a set margin over BMO CAD Prime Rate, or a Bankers' Acceptance of appropriate term.

The Company has the option to upsize the facility to $250 million, subject to certain conditions. The debt facility is primarily secured by Aurora's production facilities and can be repaid without penalty at Aurora's discretion.

• New York Stock Exchange ("NYSE") Listing
  On October 23, 2018, the Company's common shares commenced trading on the NYSE under the ticker symbol "ACB". This milestone reflects Aurora's commitment to continue advancing domestic and internal growth initiatives, which includes expanding the Company's base of global institutional and retail investors.

Financial Review Q1 2019

The Company primarily operates in the cannabis market which includes auxiliary support functions such as CanvasRX patient counselling services; ALPS design, engineering and construction services; and cannabis analytical product testing services through the Company's recent acquisition, Anandia Laboratories Inc. ("Anandia"). With the Cannabis Act effected as of October 17, 2018, Aurora made its first shipments to provinces across Canada at the end of September 2018.

In the first quarter of 2019 ("Q1 2019") total medical cannabis revenue grew to $24.0 million, a 62% increase compared to the fourth quarter of 2018 ("Q4 2018") and a 229% increase compared to the first quarter of 2018 ("Q1 2018"). With the Cannabis Act in effect as of October 17, 2018, the Company completed its first shipments to Canadian provincial wholesalers of the adult-use market just prior to the end of the current quarter and recorded $0.6 million in adult-use cannabis sales.

Total revenue grew to $29.7 million in Q1 2019, representing a 55% increase compared to Q4 2018 and a 260% increase compared to Q1 2018. Revenue growth compared to the same quarter in the prior year was attributable mainly to higher patient numbers following the acquisition of CanniMed and MedReleaf, increased product availability through scale up of operations from the CanniMed and MedReleaf acquisitions, an increase in the average net selling price of dried cannabis, development of international markets, the commencement of the Canadian adult-use market, and product diversification.

The average net selling price of cannabis sold was $9.19 per gram in Q1 2019, consistent with Q4 2018, and a 12% increase compared to Q1 2018 as a result of an increase in cannabis extracts sold. Total product sold was 2,676 kilograms of dried cannabis and cannabis extracts in Q1 2019, an increase of 65% as compared to Q4 2018, and 201% compared to Q1 2018.

Total cannabis inventory and biological assets increased 97% to $80.8 million in Q1 2019 compared to Q4 2018 as Aurora chose to constrain international sales in order to continue servicing the Canadian medical market, while building inventory in preparation for the Canadian adult consumer-use market. The increase reflects the addition of MedReleaf's inventory and biological assets and Aurora's efforts to bolster its inventory levels to serve the medical markets and prepare for the high demand of the Canadian adult consumer-use market.

Cost of sales

Cash cost of sales per gram of dried cannabis sold increased by $0.03 to $1.90 in Q1 2019 as compared to the prior quarter (Q4 2018), mainly due to higher packaging costs from the inclusion of MedReleaf's results and increased overall packaging costs of the Company resulting from stringent regulatory requirements of the Cannabis Act. Cash cost to produce per gram of dried cannabis sold decreased by $0.25, or 15%, to $1.45 in Q1 2019 as compared to Q4 2018, and by 22% as compared to Q1 2018, mostly due to integration of Aurora's yield expertise at CanniMed facilities. Production costs per gram are expected to decrease significantly once Aurora Sky is fully operational and the efficiencies from automation, scale and yield expertise are realized at all Aurora facilities.

Gross Profit

Q1 2019 gross profit was $8.1 million, compared to a $20.6 million in Q4 2018. The change in gross profit during the period was partially attributable to higher sales of inventory and lower fair value gains on changes in biological assets, which were partially offset by higher gross profits before fair value adjustments.

Operating Expenses

Aurora continues to make significant investments in its infrastructure and skilled talent, scaling the organization to better realize the tremendous opportunities ahead in the global medical cannabis markets and the Canadian adult consumer-use market.

As a result, general and administration costs ("G&A") increased to $35.9 million in Q1 2019, compared to $22.6 million in Q4 2018. Sales and marketing costs (S&M) in Q1 2019 increased to $29.4 million dollars, from $14.8 million in Q4 2018, mainly as a result of certain one-time activities and programs specifically for the period leading up to the October 17, 2018 Cannabis Act effective date in Canada. The integration of CanniMed accounted for 17% of the increase to G&A and 12% of the increase to S&M.

Net Income

Q1 2019 net income increased to $104.2 million, compared to a net income of $79.3 million in Q4 2018 and $3.6 millionin Q1 2018. The increase was primarily attributable to the unrealized non-cash gain on derivatives and marketable securities, which was partially offset by increased finance costs, share-based payments, acquisition and project evaluation costs.

Cash Position, Cash Flows, and Working Capital

Net cash and cash equivalents on hand increased from $89.2 million at the end of Q4 2018 to $147.8 million as at Q1 2019. Working capital at the end of Q1 2019 was $548.4 million, as compared to $144.5 million at the end of Q4 2018. The change in working capital was largely attributable to an adjustment to the Company's investment in The Green Organic Dutchman ("TGOD"), which was previously treated as an investment in associate and was reported at cost; the investment is now treated as a marketable security and reported at fair value. The inclusion of MedReleaf's balances accounted for $57.6 million in additional working capital.

The Company also has strategic investments in a number of publicly-traded companies. Based on the closing prices at November 9, 2018, the value of the common shares and "in-the-money" warrants held by the Company was $407.57 million.

The Company anticipates that it has sufficient liquidity and capital resources to meet all of its currently planned expenditures for at least the next twelve months.

Pro-Forma Reconciliation

For the three months ended June 30, 2018, pro-forma revenue, including the results of MedReleaf, Anandia Labs, and Agropro/Borela, would have been $35.8 million.

Outlook

Aurora is exceptionally well‑positioned in all of its active markets, including adult consumer-use market, Canadian medical and the international medical markets, with compelling brands, a broad and expanding product portfolio, and strong patient and consumer recognition.

In fiscal 2019, the Company will continue to focus on expanding capacity and sales growth in all its markets, in addition to exploiting further product development and innovation, medical research, continued international expansion and realization of acquisition synergies.

Aurora is rapidly accelerating production out of its newly licensed facilities, starting with Aurora Sky, which is expected to ramp to full 100,000 kg per annum capacity over the coming months. The Company anticipates reaching a production run rate of approximately 150,000 kg per annum early in calendar 2019, scaling up subsequently to over 500,000 kg per annum (excluding additional capacity through the pending ICC Labs acquisition) through further "Sky Class" facilities, Aurora Sun and Aurora Nordic. The high degree of automation, and customized and fully controlled growing conditions at the Sky Class facilities are anticipated to result in production costs well below one dollar per gram. Management believes these factors together will deliver high growth and continuously improving margins.

While the historic milestone of Canada becoming the first G7 nation to legalize the adult consumer-use market creates a very significant growth opportunity, the Company maintains its position that long term the international medical market has the most significant growth prospects, and is expected to grow to 10 million kilograms per annum according to industry observers. The Company has established significant early mover advantage, has a presence on five continents, and is currently Europe's largest distributor of medical cannabis. Aurora also currently owns two of the seven cannabis production facilities in the world that are EU GMP certified, and additionally owns one EU GMP certified distribution facility in Germany, ensuring continued access to restrictive markets. Management believes this early mover advantage, coupled with the strength of its growing international management teams, will enable the Company to continue expanding its significant market share in the global medical market.

Option Grant
The Company granted a total of 250,000 options to purchase common shares of Aurora to Officers of the Company. The options vest annually over 36 months and are exercisable at $9.94 per common share.

Conference Call
Aurora will host a conference call today, November 12, 2018, to discuss these results. Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, and Cam Battley, Chief Corporate Officer, will host the call starting at 10:30 a.m. Eastern time. A question and answer session will follow management's presentation.

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 19 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and the pending acquisition of ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

Terry Booth, CEO
Aurora Cannabis Inc.,

Forward looking statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the adult use market.. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor NYSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and the New York Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

[Blocked Image: https://rt.newswire.ca/rt.gif?…APR_C7486&DateId=20181112]

For further information: For Media: Heather MacGregor, +1.416.509.5416, heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, +1.647.269.5523, marc.lakmaaker@auroramj.com; Rob Kelly: +1.647.331.7228, rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, Phone: (212) 896-1233 / (212) 896-1203, Email: pcarlson@kcsa.com / ebarker@kcsa.com

https://www.sec.gov/Archives/e…79569-18-002342-index.htm

EX-99.1 2 ex991.htm NEWS RELEASE DATED NOVEMBER 22, 2018

Exhibit 99.1

[Blocked Image: https://www.sec.gov/Archives/e…0127956918002342/logo.jpg]

Aurora Cannabis Receives Final Regulatory Approval and Completes Acquisition of ICC Labs

Establishes Leadership Position and Platform for Growth in Latin American Market

TSX | NYSE: ACB
TSX-V: ICC

EDMONTON, Nov. 22, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or "the Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) and ICC Labs Inc. (TSX-V: ICC) ("ICC") are pleased to announce today the completion of the previously announced plan of arrangement (the "Arrangement") pursuant to which Aurora has acquired all of the issued and outstanding common shares of ICC for $1.95 per share (payable in common shares of Aurora (the "Aurora Shares")), reflecting an aggregate purchase price of approximately $290 million. ICC is now a wholly-owned subsidiary of Aurora. Completion of the Arrangement follows receipt of approval of the Arrangement from the Instituto de Regulación y Control del Cannabis, the Uruguayan regulatory authority overseeing the regulation and control of cannabis in Uruguay.

ICC's common shares will be delisted from the TSX Venture Exchange (the "TSX-V"), subject to TSX-V approval, and applications will be made for ICC to cease being a reporting issuer.

The acquisition of ICC establishes Aurora as the industry leader in Latin American, a region which encompasses more than 650 million people from across Mexico, the Caribbean, Central America, and South America. ICC, based in Uruguay, the first country in the world to legalize cannabis for adult consumer use, has developed a strong portfolio of high-quality, low-cost production assets, product offerings, and commercial agreements. Located in Uruguay's free trade zone, ICC's state-of-the-art science and GMP compliant processing facility, the first of its kind in Latin America, brings very significant capacity and early mover advantage to build significant market share both in Latin America and the international cannabis and wellness markets.

Management Commentary

"This transaction combines two pioneering cannabis companies with fully aligned international growth ambitions, immediately positioning Aurora as the market leader in Latin America, an area with well over 650 million people," said Terry Booth, CEO of Aurora. "Not only does ICC have substantial low cost, high-quality production capacity, it is the first company in Latin America which has completed a GMP compliant extraction facility, which will play an important role in supplying higher-margin CBD-based products for the global cannabis and wellness markets. Together, ICC and Aurora will accelerate the development of our well-diversified product portfolio, and extensive distribution channels to capitalize on the substantial opportunities in the global cannabis industry."

Neil Belot, Chief Global Business Development Officer, added "Alejandro and his team have developed one of the deepest international networks Aurora has encountered. ICC has leveraged its early mover advantage in Uruguay to capitalize on significant growth opportunities in the broader Latin American cannabis markets. With world-class production, process facilities and distribution infrastructure in place, this transaction strengthens Aurora's position as the global partner of choice in multiple international markets."

Alejandro Antalich, CEO of ICC Labs added, "The complementary nature of our two organizations makes this transaction an ideal fit that will allow us both to realize our ambitious growth strategies. We're excited to announce our upcoming official grand opening of the first state-of-the-art laboratory in Latin America on November 28th. This facility based in Uruguay is focused on the development of pharmaceutical grade products derived from cannabis and hemp. With our Latin American facilities coming online, as well as multiple supply and distribution agreements in large international markets in place, we believe that Aurora's resources, innovation capabilities, and broad global distribution networks represent an ideal partner to accelerate our growth."

ICC brings to Aurora, among other strategic synergies, the following competitive advantages.

Significant, Low-cost Capacity

• Significant expansion of low-cost production and processing capacity: ICC is expanding rapidly, with both established facilities and a number of projects in various stages of completion that will bring the estimated production capacity of cannabis and hemp to over 450,000 kg per annum, adding significant value to Aurora's funded footprint:
  • Two operational greenhouse facilities totaling approximately 92,000 square feet
  • Three outdoor grow sites, with a total potential area of over 800 acres, 590 acres of which are in Uruguay and which are being prepared for cultivation start later this calendar year
  • The Company is assessing integration and development synergies between ICC and its wholly owned subsidiary MED Colombia, including the construction of greenhouse and processing facilities, and is developing its plan for a 1,000,000 square foot greenhouse facility in Uruguay, and a similarly sized facility in Colombia.

Strong Foundation to Capitalize on the Significant Global CBD Wellness Market Opportunity

• CBD Rich Production: Uruguay is the only country where regulations currently permit the cultivation of CBD-rich hemp on a commercial scale, allowing licensed producers to grow hemp with THC concentrations of up to 1%, providing a significant yield advantage over global competitors. ICC's deep background in pharma and the ability to grow low-cost CBD-rich hemp at very large scale, position Aurora exceptionally well to capitalize on global opportunities in the high-growth CBD wellness market.
• CBD Brand and Distribution: ICC recently launched its BIDIOL brand of CBD products, and is developing a broad international distribution network.
• Significant Extraction Capacity: ICC has completed a state-of-the-art large-scale extraction facility with capacity to process 150,000 kg of CBD feed per annum.
• Free Trade: ICC's new CBD extraction facility is strategically located approximately five minutes from the Canelones international airport and within Uruguay's "Science Park" free trade zone. This strategic location exempts all facility exports from any applicable local tax on exports and imports.

Science, High-margin Products and Strong Genetics

• The First Latin American GMP Compliant Science Lab: ICC has completed Latin America's first state-of-the-art cannabis science laboratory, designed to the highest international standards and in compliance with applicable GMP standards. In the process of being certified, the facility will provide an early mover advantage over other producers in Latin America to drive sales to international cannabis markets. The Company has received the required registration and government permits to commence operation of the facility.
• Product Diversification: ICC offers a broad portfolio of dried flower and higher margin products, including tablets, softcaps, ointments, creams, drops, infused syrups, and patches. The Company is assessing pathways for potential import of products and IP into Canada.
• Genetics: ICC has secured an exclusive portfolio of high CBD strains, including exclusivity in South America for CW2A-B, a high-profile CBD strain.

Full details of the Arrangement and certain other matters are set out in the management information circular of ICC dated October 3, 2018 (as updated by the news release of ICC dated October 15, 2018) (the "ICC Circular"). A copy of the ICC Circular and other meeting materials can be found under ICC's profile on SEDAR at http://www.sedar.com.

Under the Arrangement, each holder of common shares of ICC ("ICC Shareholder") has received approximately 0.2161 Aurora Shares for each common share of ICC held and Aurora has issued a total of 31,904,668 Aurora Shares pursuant to the Arrangement (not giving effect to the exercise of any ICC Compensation Options or ICC Warrants, as such terms are defined in the arrangement agreement dated September 8, 2018 between ICC and Aurora), which as of November 21, 2018 represented approximately 3.20% of the outstanding Aurora Shares after giving effect to the Transaction.

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per annum and sales and operations in 20 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

About ICC

ICC is a fully licensed producer and distributor of medicinal cannabinoid extracts, adult usage cannabis and industrial hemp products in Uruguay as well as a fully licensed producer of medicinal cannabis in Colombia. ICC has active operations in Uruguay, and is focused on becoming a worldwide leading producer of cannabinoid extracts, giving support and promoting responsible use for medicinal purposes, backed by scientific research and innovation, while following strict compliance with standards for quality and safety.

Neither the TSX, NYSE, TSX-V nor their Regulation Services Provider (as that term is defined in the policies of the TSX, NYSE, and TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Caution Concerning Forward-Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to statements with respect to: results of operations, anticipated benefits and cost synergies associated with the Transaction, internal expectations, estimated margins, expectations for future growing capacity, costs and opportunities, the effect of the Transaction on the combined company and its future strategy, plans, objectives, goals, targets and future developments, the completion of any capital projects or expansions, the anticipated timing for the de-listing of ICC from the TSX-V and for ICC to cease to be a reporting issuer and the expected benefits of the Arrangement.

ICC Shareholders are urged to carefully read the management information circular of ICC dated October 3, 2018 (as updated by the news release of ICC dated October 15, 2018) and related materials in their entirety as they contain important information regarding the Arrangement and its consequences to ICC Shareholders.

Forward-looking statements are based on the opinions and estimates of management of ICC and Aurora at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statement, whether expressed or implied, including, without limitation: inability to realize anticipated synergies; future legislative and regulatory developments involving cannabis; the cannabis industry in Canada and elsewhere generally; income tax and regulatory matters; the ability of ICC and Aurora to implement their business strategies; competition; crop failure; currency and interest rate fluctuations; failure to realize the expected benefits of the Arrangement; compliance with all applicable laws and other customary risks associated with transactions of this nature; and general economic conditions. Forward-looking statements should be considered carefully and undue reliance should not be placed on them.

Management of Aurora and ICC provide forward-looking statements because they believe they provide useful information to readers when considering their investment objectives and cautions readers that the information may not be appropriate for other purposes. Consequently, all of the forward-looking statements made in this news release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, ICC and Aurora. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management of Aurora and ICC at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

These forward-looking statements are made as of the date of this news release and each of ICC and Aurora assume no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as expressly required by applicable law.

[Blocked Image: https://www.sec.gov/Archives/e…56918002342/image_001.jpg]

ICC Labs Inc. (CNW Group/Aurora Cannabis Inc.)

[Blocked Image: https://www.sec.gov/Archives/e…56918002342/image_002.jpg]View original content to download multimedia:http://www.prnewswire.com/news…f-icc-labs-300754704.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/rele…ovember2018/22/c7061.html

%CIK: 0000168354

For further information: For Media: Heather MacGregor, (416) 509-5416, heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, (647) 269-5523, marc.lakmaaker@auroramj.com; Rob Kelly, (647) 331-7228, rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, (212) 896-1233 / (212) 896-1203, pcarlson@kcsa.com / ebarker@kcsa.com; For ICC: Alejandro Antalich, CEO, (598) 2900-0000 ext. 404, ir@icclabs.com

CO: Aurora Cannabis Inc.

CNW 17:58e 22-NOV-18

ACB

Danke euch. Hier noch etwas zu ACB/Aurora: *dirol*

Aurora in the Media: Your Money Australia

Cam Battley, CCO, appears on Your Money to discuss the medical cannabis system in Australia and the country’s potential to become a global industry leader alongside Canada. Also discussed is Cann Group, Australia’s leading LP and partner to Aurora, and its plans to not only supply medical cannabis to the domestic market, but to ultimately become an exporter.
Click here to watch the video.

Aurora / Ergebnis

Emil hat am 25.09.2018 08:50 geschrieben:

Quote

Danke at Shanik82 für Info oben.

Aurora s. Link, Text ist lang, aber super *clapping*:

https://www.newswire.ca/news-r…iscal-year-694175781.html

Presse / Kurzfassung:

By Max A. Cherney

Published: Sept 24, 2018 6:10 p.m.

Tech reporter

Aurora Cannabis Inc. ACBFF, +2.64% ACB, +3.63% released fiscal fourth-quarter earnings late Monday and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange. "Listing our shares on a senior U.S. exchange reflects the level of corporate and business maturity and our high-paced execution," Aurora Chief Executive Terry Booth said. "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success." The company's top line grew 223% to C$19.1 million, up from C$5.9 million in the year-earlier quarter. Aurora logged earnings of C$79.9 million, up from losses of C$4.8 million in last year's quarter; in its financial statements Aurora said the quarter's profits were related to unrealized non-cash gains on derivatives and other marketable securities. Gross profit was C$20.6 million, up from C$5.8 million in the year-ago quarter. The company said it produced 2,212 kilograms of pot and sold 1,617 kilograms, up 90% and 114% respectively compared with the year-earlier period. Aurora stock is listed on the pink sheets in the U.S. and on the TSX. Toronto-listed shares have gained 28% this year, as the S&P 500 index SPX, -0.35% rose 9.2%.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Quelle:https://www.marketwatch.com/st…9-24?mod=newsviewer_click

Display More

Danke @ Emil für Info

Ist echt gut gekommen *smile* *dirol* , hier noch was:

https://www.newswire.ca/news-r…ry-leaders-694257241.html

Auroa-News heute

Aurora / ACB

News

Aurora Cannabis Completes Distribution of Australis Capital

EDMONTON, Sept. 19, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM), today announced that it has completed its previously announced distribution of Australis shares and warrants (the "Distribution"). The distribution was completed on September 19, 2018, and the Australis shares and warrants will commence trading on the CSE under the symbol "AUSA" effective at the market open today.

In accordance with the terms of the Distribution, eligible Aurora shareholders were paid one unit of Australis for every 34 Aurora shares outstanding as at August 24, 2018 (the "Record Date). Each unit consists of one common share and one share purchase warrant of Australis. Each warrant entitles the holder thereof to acquire one share at an exercise price of $0.25 per Australis share, on or prior to 4:00 p.m. (Eastern Time) on the date that is one year after the Distribution.

As described in further detail in the Final Prospectus, no units were issued to shareholders who are (or were deemed to be) non-residents of Canada. Rather, such units have been delivered to a custodian for sale in the open market following the Distribution, and the net cash proceeds will be delivered to non-resident shareholders, net of any withholding taxes.

Following the distribution, Aurora has no direct ownership interest in Australis, and the company is an independently operating entity. Aurora, however, does hold two warrants, allowing the Company to acquire an ownership interest at such time in the future (within 10 years) when holding investments in U.S. cannabis assets will become permissible.

"With the completion of this distribution we have delivered an immediate return of capital to Aurora shareholders while enabling the Australis team to proceed with their mandate to invest in U.S. cannabis assets with high growth potential," said Terry Booth, CEO of Aurora. "Australis' management, board of directors and investment committee are well positioned to leverage their collective knowledge and extensive experiences to rapidly execute on the tremendous opportunity ahead to generate substantial long-term shareholder value."

Scott Dowty, CEO of Australis, added, "We will leverage the opportunities created by a fragmented U.S. cannabis market with limited access to growth capital. We have not wasted time and have already identified a number of strong assets within this market that we believe have high growth potential. With the completion of our over-subscribed private placement, we have the funds to start executing on these opportunities immediately and deliver growth."

About Aurora

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 500,000 kg per year and sales and operations in 18 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland (formerly Pedanios), have achieved this level of certification.

In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 15 companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland (formerly Pedanios), H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, Agropro, Borela, and the pending acquisition of ICC Labs – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com, Twitter, Facebook or Instagram

Terry Booth, CEO
Aurora Cannabis Inc.

About Australis

Australis Capital identifies and invests in the cannabis industry predominately in the United States, a highly regulated, fragmented, fast growing and evolving industry. Investments may include and are not limited to equity, debt or other securities of both public and private companies, financings in exchange for royalties or other distribution streams, and control stake acquisitions. Australis Capital adheres to stringent investment criteria and will focus on significant near and mid-term high-quality opportunities with strong return potentials while maintaining a steadfast commitment to governance and community. Australis Capital's Board, Management and Advisory Committee members have material experience with, and knowledge of, the cannabis space in the U.S., extensive backgrounds in highly regulated industries, adherence to stringent regulatory compliance, public company and operational expertise. For more information, please visit us at www.ausacap.com.

und

Presse: / Quelle:

https://www.profitconfidential…-cola-us-listing-october/

Coca-Cola Partnership

It’s been a hectic week for marijuana stocks so far, with a lot of news dropping on a variety of fronts. But none has been more impactful than the rumors that The Coca-Cola Co (NYSE:KO) is looking to enter the marijuana industry and could choose Aurora Cannabis Inc (OTCMKTS:ACBFF, TSE:ACB) as its vessel. Needless to say, the potential Coca-Cola partnership proved to be a massive boon to the Aurora stock forecast.

Reports have come in that Coca-Cola is in talks with Aurora to produce non-alcoholic, cannabis-infused beverages. As a result, Aurora Cannabis stock climbed swiftly, surging 10% when the reports came in, while KO stock hasn’t seen much movement since the talks were announced. (Source: “Coke, Aurora Cannabis in talks to make marijuana-infused drinks: BNN Bloomberg,” CNBC, September 17, 2018.)

Should the partnership come to fruition, the two would likely develop health-focused beverages that will ease inflammation, pain, and cramping, the report stated.

“Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD [cannabidiol] as an ingredient in functional wellness beverages around the world,” The Coca-Cola Co said in a statement. “No decisions have been made at this time.”

Advertisement

Aurora also declined to give specifics about a potential deal, but did say that it, “has expressed specific interest in the infused beverage space, and we intend to enter that market.” (Source: Ibid.)

This marks the first time a non-alcoholic beverage company has looked into the marijuana sector.

Considering how positive investments have been received by the alcohol industry, the soft-beverage sector now looking to enter the marijuana market is only going to drive marijuana stock prices even higher.

After all, the $3.8-billion investment by Constellation Brands, Inc. (NYSE:STZ) into Canopy Growth Corp (NYSE:CGC) was enough to turn the entire industry around and push dozens of percentage points of growth across multiple stocks.

Should Coca-Cola be planning to invest, expect to see a major surge in marijuana prices as more concrete details filter out.

But the potential Coca-Cola deal is not the only positive news to have come out of Aurora Cannabis stock lately.

While likely to be the most momentous, several other positive moves by the company have brightened the Aurora Cannabis stock forecast considerably.

Hemp Leadership in Europe

One of the more recent boons to the Aurora Cannabis stock forecast came by way of the company’s deal with Agropro UAB, Europe’s largest producer, processor, and supplier of organic hemp and hemp products.

The Agropro acquisition provides Aurora with access to 1,600 hectares of land to grow a potential 1,000,000 kilograms of hemp, while Agropro is also looking into expanding into Lithuania, Latvia, Estonia, and Poland, potentially adding another 3,000 hectares. (Source: “Aurora Cannabis Acquires Europe’s Largest Organic Hemp Company,” Cision, September 12, 2018.)

The deal will open up Agropro to exploiting the CBD components of its hemp.

Aurora is planning to use that formerly discarded hemp biomass containing CBD to create a number of wellness products.

? WEED/CGC

@Petra

Hast du einen Link zur Info oder den Text. Es wäre nett, wenn wir das sehen könnten. Danke.

ACB Toronto

Ich bin nun da auch dabei, Aurora dürfte steigen.

Grüsse von fern zurzeit

CGC-Q1/2019 Ende Juni 2018

CGC-Zahlen Q1: Da der Text und die Zahlen umfangreich sind, s. Link, *dirol* *smile*

https://www.sec.gov/Archives/e…127956918001720/ex991.htm

https://www.sec.gov/Archives/e…79569-18-001720-index.htm

https://seekingalpha.com/pr/17…al-2019-financial-results

Info CGC / Termin für Zahlen

ACB-News

Emil

Danke für die Info oben.

Aurora (News von gestern):

Aurora Cannabis Announces $200 Million Debt Facility with BMO

Major Non-Dilutive Financing Deal with Canadian Tier 1 Bank Represents Significant Milestone in the Cannabis Sector

EDMONTON, June 26, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) announced today that it has agreed to a new $200 million debt facility, with a potential upsize to $250 million, with the Bank of Montreal ("BMO").

The facility will consist of a $150 million term loan and a $50 million revolving credit facility (together, the "Loans"), both of which will mature in 2021. A short period after the implementation of Bill C-45 in October 2018, the Company may request an increase of up to a further $45 million to the term loan subject to agreement by BMO and satisfaction of certain legal and business conditions. BMO will also be providing up to $5 million in other credit instruments. Closing of the debt facility is subject to completion of final due diligence, negotiation of definitive documentation, and satisfaction of conditions precedent customary to a financing of this nature.

The debt facility will be primarily secured by Aurora's production facilities, including Aurora Sky, Aurora Mountain, and Aurora Vie. Strategically located at Edmonton International Airport, Aurora Sky is the world's most technologically advanced cannabis facility, projected to produce in excess of 100,000 kg per year of high-quality cannabis at low per gram costs, and slated to deliver its first harvest this week.

"Having successfully met all of BMO's stringent risk assessment and other due diligence criteria to establish this facility reflects well on the maturity, progress and prospects of Aurora, as well as the quality and economic value of our production facilities," said Terry Booth, CEO. "This is by far the largest traditional debt facility in the cannabis industry to date. The funds provide us additional fuel to complement our end-to-end portfolio of vertically integrated, geographically and horizontally diversified assets, aimed at building a pre-eminent global cannabis company with a superior margin profile."

Glen Ibbott, CFO of Aurora, added, "The shift to traditional debt financing is significant. Our cost of capital continues to decrease, providing us a distinct competitive advantage as we execute on our growth strategy. The non-dilutive nature and attractive pricing are consistent with Aurora's commitment to generating shareholder value. We believe this is a major milestone in the cannabis industry and a validation of our operational effectiveness. It also marks an exciting new stage of our long-term relationship with BMO, a Tier 1 bank with a sterling domestic and international reputation."

The Loans can be repaid without penalty at Aurora's discretion. The pricing of the Loans is a set margin over the BMO CAD Prime Rate or a Bankers' Acceptance of appropriate term. Based on the current BMO CAD Prime Rate, the interest payable is expected to be in the mid to high 4% per annum range over the term of the Loans.

More details on this new sector benchmark debt facility can be found in the Company's documents once filed on www.sedar.com.

News heute:

https://petitions.ourcommons.c…n/Details?Petition=e-1528

Und Anfang diese Woch noch ein Video:

https://www.youtube.com/watch?v=hJgB-rgDuu4

Legalisierung / Cannabis ist durch

*biggrin* *dirol*

Heute:

Dienstag, 19.06.2018 - 20:16 Uhr

Cannabis-Aktien gehen durch die Decke!

Heute machen die Cannabis-Aktien erneut einen kräftigen Sprung nach oben. Der Grund hierfür ist in Canada zu finden. Die Legalisierung von Cannabis ist durch! >

https://www.godmode-trader.de/…n-durch-die-decke,6157803

Quelle:

https://news.guidants.com/#!Ticker/Feed/?r=1

ACB-News

Ja, hier geht was zurzeit:

Info heute:

Aurora Cannabis to acquire 8% of Choom Holdings

2018-06-13 08:02 ET - News Release

Mr. Terry Booth reports

AURORA CANNABIS TO BE LEAD INVESTOR IN CHOOM HOLDINGS PRIVATE PLACEMENT

Aurora Cannabis Inc. intends to complete a $7-million investment in Choom Holdings Inc., whereby Aurora will receive 9,859,155 common shares from Choom's treasury, priced at 71 cents per share, representing an 8-per-cent ownership interest.

Choom currently operates two late-stage applicants under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Choom has agreements in place to acquire two additional late-stage applicant craft growers in British Columbia and Saskatchewan, including a facility in Sooke, B.C., anticipated to receive its cultivation licence from Health Canada in the third quarter of 2018.

The relationship between Aurora and Choom germinated through Aurora Pro, the platform through which the company delivers a variety of services to industry participants, including cultivation, genetics, regulatory consultancy and market development services. The Aurora Pro platform was developed by Aurora to interact with craft growers who are faced with potentially unreasonable entry barriers to the adult usage market in Canada.

Choom's strategy is to develop a carefully curated portfolio of high-grade cannabis strains with ideal characteristics for craft growing, targeting the premium segment of the adult consumer use market. Choom continues to develop a sophisticated brand, high-grade products and an elevated in-store customer experience. Images of the company's concept cannabis retail outlets can be found on-line.

To date, Choom has secured rights to 17 retail leases in highly defensible locations throughout Alberta. Applications to obtain a cannabis retail licence for these outlets have been submitted. Choom also has seven leases secured in B.C. and licences will be applied for upon commencement of the licensing program in B.C. Choom furthermore intends to play an important role in the Saskatchewan retail market and has a robust strategy in place to develop its presence in this market.

Management commentary

"Our investment in a consumer-focused brand with a strong retail strategy offers Aurora additional growth opportunities through supply, retail and distribution to the adult consumer use market, and provides a good example of the functioning of Aurora Pro," said Terry Booth, chief executive officer of Aurora. "Choom has established a well-developed brand, supported by deep roots within the British Columbia cannabis community and a passion for high-grade, handcrafted product. We're excited to strengthen our relationship with the team at Choom and help amplify their market reach as they continue to execute on their differentiated craft growing philosophy and their unique retail strategy."

Chris Bogart, president and CEO for Choom, added: "Teaming up with what we consider to be the most dynamic licensed producer with exceptional strength throughout the entire cannabis value chain, we believe, will prove to be a key growth accelerator for Choom. Both companies have a very strong focus on the entire customer experience, key in establishing exceptional brands. This investment by Aurora is a strong signal to our markets and our shareholders that Choom's strategy meets with the highest standards in the industry."

About Aurora Cannabis Inc.

Aurora's wholly owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, known as Aurora Mountain, and a second 40,000-square-foot high-technology production facility known as Aurora Vie in Pointe-Claire, Que., on Montreal's West Island. In January, 2018, Aurora's 800,000-square-foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed by Health Canada. Once at full capacity, Aurora Sky is expected to produce over 100,000 kilograms per annum of cannabis.

About Choom Holdings Inc.

Choom was created for and inspired by the Choom gang, a group of buddies in Honolulu during the 1970s who loved to smoke weed -- or as the locals called it, choom. Now, after four decades, Choom is bringing the spirit of Hawaii to Canada. Choom is focused on delivering an elevated customer experience through its curated retail environments, high-grade handcrafted cannabis supply and a diversity of brands for the Canadian recreational consumer.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.

Dann war da noch:

http://www.stockhouse.com/news…-waste-digester-to-aurora

ACB-Info

Dies wollte ich noch mitteilen:

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event through VirtualInvestorConferences.com

EDMONTON, Alberta, June 5, 2018 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that Cam Battley, Chief Corporate Officer will present live at VirtualInvestorConferences.com on June 7, 2018.

DATE: Thursday, June 7, 2018
TIME: 12:00 PM ET
LINK: https://tinyurl.com/0618prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Recent Company Highlights

• Aurora Cannabis to Acquire MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted, in the money basis.
• Launched a new product line called Aurora Frost. This new dried cannabis product line represents the highest potency offering of any Aurora product launched to date at over 35% THC.
• The Company, through its wholly owned subsidiary Pedanios GmbH, has signed a collaboration agreement with Heinrich Klenk GmbH & Co. KG ("Klenk"), one of Europe's largest medicinal plant companies. Under the terms of the agreement, Aurora has launched a new cannabis brand in Germany called "Cannabis Klenk" which is produced in Canada, imported by Pedanios, and sold to German pharmacies through Klenk's existing and wide-reaching pharmaceutical wholesale distribution network.
• Aurora is acquiring an initial 9.14% ownership interest in and CTT Pharmaceutical Holdings Inc, a global leader in the development of dose specific fast dissolving oral thin film wafers that provide a quick release, smoke-free delivery of medical cannabis or other active ingredients.

The Cannabis Virtual Investor Conference on June 7, 2018 is made possible by a partnership between KCSA Strategic Communications and VirtualInvestorConferences.com. Learn more about the event at www.VirtualInvestorConferences.com.

ACB-Nesw / CGC-News

Lorenz

Du hast Recht, man sollte Aurora auch nicht aus den Augen lassen, ich habe sie. (Bei CGC/WEED) bin ich seit dem US-Börsenstart mal weg).

Aurora Cannabis Launches New Cannabis Product Line – Aurora Frost

Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announces the launch of new product line called Aurora Frost . This new dried cannabis product line represents the highest potency offering of any Aurora product launched to date at over 35% THC.

Aurora Frost products are produced from premium whole flower. The products, generally known throughout the industry as kief, consist primarily of trichomes, the resinous glands rich in active pharmaceutical ingredients, including terpenes, flavonoids, and cannabinoids, such as THC and CBD.

Aurora’s in-house technology team successfully developed a new and proprietary technology used to efficiently produce high volume, GMP compliant, Aurora Frost products, based on a process that finely trims the trichomes from the cannabis flower.

Beginning today, Aurora Frost is shipping in convenient, child-safe, certified glass bottles. Products are sold in one gram increments, priced at $35 per gram ( $25 per gram for compassionate pricing patients). Like all Aurora products, Aurora Frost comes with publicly available third party independent laboratory results on potency, terpene profile, and contaminant analysis.

“Successfully developing a proprietary, fine trimming and GMP compliant technology needed to produce these high-quality products at commercial scale, provides us with a remarkable advantage in addressing this niche of the cannabis market,” said Terry Booth , CEO. “Aurora now makes this high potency medical cannabis available to its patients, reflecting the Aurora Standard of innovation and patient care.”

SMITHS FALLS, ON, May 30, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to announce that the Company has acquired Daddy Cann Lesotho PTY Ltd., trading as Highlands ("Highlands").

Based in the Kingdom of Lesotho ("Lesotho"), Highlands holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and its resin. Lesotho is a high altitude mountainous kingdom that boasts over 300 days of sunshine per year and was the first African nation to legalize medical cannabis in 2017. It has ideal humidity and growing conditions for greenhouse cultivation. Together with very low operating and resource costs, this places Canopy Growth in a position to produce large quantities of high quality medical cannabis at a low cost. Lesotho is also strategically positioned for the future medical cannabis economy of Southern Africa including the potential market of South Africa, with a population of over 55 million people, where medical cannabis laws are being developed.

"Lesotho is Canopy Growth's first step into Africa and we look forward to working with the strong local team at Highlands to establish production and distribution capabilities consistent with Canopy's global standard for high-quality, regulated medical cannabis products," said Mark Zekulin, President, Canopy Growth.

Combining the domestic and regional knowledge of Highlands with the global experience and expertise of Canopy Growth is the latest example of the Company establishing a meaningful local presence. With the objective of future local production to serve the regional market, these operations are part of Canopy Growth's commitment to the Lesotho economy including supporting job creation and lasting community engagement.

All key members of Highlands's management team will continue to lead the organization as part of the Canopy Growth family.

"We're excited to join the Canopy Growth family and bring together our strong entrepreneurial experience and local knowledge in the region with Canopy Growth's track record and quality standards in the global medical cannabis industry," said Jody Aufrichtig, Founder, Highlands. "Lesotho and Southern Africa have enormous potential and we look forward to building a responsible medical cannabis business across the region."

Under the terms of the agreement, the Company issued 666,362 common shares in the capital of the Company to the sole shareholder of Highlands on closing and, subject to meeting certain milestones, the Company will issue up to an additional 333,281 common shares to the sole shareholder of Highlands for a total of up to 999,643 common shares based on the 30 day volume weighted average price of $28.763 of Canopy Growth's common shares on the TSX as of May 11, 2018. The total value of the consideration payable by the Company under the terms of the agreement is approximately $28.8 million.

This marks the fifth continent of operations for Canopy Growth who has market presence in North and South America, Oceania, Europe, and now Africa.

Here's to Future Growth (in Southern Africa).

CGC / ACB

Lorenz

Ja, das sind auch etwas meine Bedenken. Der Start in NY ist heute:

SMITHS FALLS, ON, May 23, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to announce that it expects its common shares will begin trading under the ticker symbol "CGC" on the New York Stock Exchange (the "NYSE") tomorrow, May 24, 2018.

This listing follows a history of firsts for the Company including being the first publicly traded, federally regulated cannabis company in North America, and the first to be included in the S&P/TSX Composite index.

Die ACB machen ihre Sache auch gut, ich denke, da darf man schon zugreifen, wer Lust hat.